Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Biotech
BioAge secures Novartis deal worth up to $550M biobucks
The Novartis deal comes less than two weeks after BioAge discarded a phase 2 obesity trial and less than three months after its Nasdaq debut.
Gabrielle Masson
Dec 18, 2024 10:44am
UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2
Dec 16, 2024 3:19pm
Novartis pays PTC $1B upfront for midphase Huntington's program
Dec 2, 2024 7:53am
Novartis signs $1.1B deal for muscular dystrophy biotech
Nov 21, 2024 8:19am
Novartis 'took data to heart' before slimming pipeline by 40%
Nov 21, 2024 5:07am
Novartis taps Vyriad’s viral vectors for in vivo T cell editing
Nov 20, 2024 12:00pm
